Published in J Am Coll Cardiol on July 23, 2007
The immune system in atherosclerosis. Nat Immunol (2011) 6.51
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 2.89
Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal (2010) 2.04
A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. Cardiovasc Res (2012) 1.63
Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2009) 1.61
The role of innate immunity in atherogenesis. J Lipid Res (2008) 1.50
Immunity, atherosclerosis and cardiovascular disease. BMC Med (2013) 1.49
Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol (2012) 1.23
Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res (2012) 1.18
Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol (2011) 1.16
Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology (2012) 1.13
Pilot study on the effect of grounding on delayed-onset muscle soreness. J Altern Complement Med (2010) 1.11
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res (2011) 1.09
B-cell aortic homing and atheroprotection depend on Id3. Circ Res (2011) 1.07
Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. J Inflamm Res (2011) 1.00
4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J (2010) 0.99
Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin Immunopathol (2009) 0.97
Immune mechanisms in atherosclerosis, especially in diabetes type 2. Front Endocrinol (Lausanne) (2013) 0.94
Immune response to lipoproteins in atherosclerosis. Cholesterol (2012) 0.90
Promise of immune modulation to inhibit atherogenesis. J Am Coll Cardiol (2007) 0.85
Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol (2008) 0.85
Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis. Open Heart (2015) 0.84
Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. J Lipid Res (2014) 0.83
Immunomodulation of vascular diseases: atherosclerosis and autoimmunity. Eur J Vasc Endovasc Surg (2010) 0.81
Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics. J Biomed Biotechnol (2010) 0.80
IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Results Immunol (2012) 0.79
Sterile inflammation in the spleen during atherosclerosis provides oxidation-specific epitopes that induce a protective B-cell response. Proc Natl Acad Sci U S A (2015) 0.79
IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice. PLoS One (2015) 0.79
Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice. PLoS One (2013) 0.78
Low levels of a natural IgM antibody are associated with vein graft stenosis and failure. J Vasc Surg (2013) 0.78
Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients. PLoS One (2014) 0.78
B Cells and Atherosclerosis. Am J Physiol Heart Circ Physiol (2017) 0.77
HDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanisms. J Lipid Res (2014) 0.76
Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases. Ther Adv Vaccines (2014) 0.76
The Homophilic Domain - An Immunological Archetype. Front Immunol (2016) 0.76
Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. Clin Res Cardiol (2014) 0.76
Does pneumococcal vaccination prevent myocardial infarction and stroke in elderly adults? Open Heart (2015) 0.75
Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells. Am J Physiol Heart Circ Physiol (2017) 0.75
Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. JACC Heart Fail (2017) 0.75
Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study. Lipids Health Dis (2010) 0.75
Once Upon a Time: The Adaptive Immune Response in Atherosclerosis-a Fairy Tale No More. Mol Med (2015) 0.75
2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in Atherosclerosis. Arterioscler Thromb Vasc Biol (2016) 0.75
Vaccine against arteriosclerosis: an update. Ther Adv Vaccines (2017) 0.75
Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae. Microbiol Immunol (2017) 0.75
Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature (2009) 3.07
Macrophage plasticity in experimental atherosclerosis. PLoS One (2010) 2.75
Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol (2012) 2.70
PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest (2012) 2.61
Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest (2002) 2.58
Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 2.56
Cardiac stem cells in the real world. J Thorac Cardiovasc Surg (2008) 2.19
The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res (2012) 2.08
Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med (2003) 1.95
KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet (2012) 1.93
High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol (2007) 1.90
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood (2007) 1.83
CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med (2004) 1.80
Parietal podocytes in normal human glomeruli. J Am Soc Nephrol (2006) 1.79
A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. Cardiovasc Res (2012) 1.63
The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med (2002) 1.62
Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 1.57
Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int (2010) 1.54
M1 macrophages act as LTβR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. Cardiovasc Res (2013) 1.54
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med (2010) 1.52
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 1.48
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood (2002) 1.46
Angiotensin II promotes thoracic aortic dissections and ruptures in Col3a1 haploinsufficient mice. Hypertension (2013) 1.43
[Immunological aspects of atherosclerosis]. Presse Med (2006) 1.39
Shortage of human intravenous immunoglobulin--reasons and possible solutions. Nat Clin Pract Neurol (2007) 1.35
Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol (2008) 1.35
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood (2004) 1.30
Metrics: journal's impact factor skewed by a single paper. Nature (2010) 1.29
Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol (2007) 1.25
PE_PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. J Immunol (2010) 1.25
Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol (2011) 1.24
Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A (2004) 1.24
Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int (2005) 1.23
Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol (2007) 1.23
Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PLoS One (2008) 1.21
Src homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responses. J Biol Chem (2010) 1.20
Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol (2011) 1.20
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Glomerular epithelial-mesenchymal transdifferentiation in pauci-immune crescentic glomerulonephritis. Nephrol Dial Transplant (2003) 1.18
Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci (2009) 1.16
Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci U S A (2005) 1.16
Reduced immunoregulatory CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol (2005) 1.15
TCR stimulation drives cleavage and shedding of the ITIM receptor CD31. J Immunol (2010) 1.15
Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol (2007) 1.14
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci (2004) 1.13
Dual role of CpG-stimulated B cells in the regulation of dendritic cells: comment on the article by Berggren et al. Arthritis Rheum (2013) 1.10
Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today (2007) 1.09
B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation (2008) 1.09
Human basophils lack the capacity to drive memory CD4⁺ T cells toward the IL-22 response. J Allergy Clin Immunol (2013) 1.09
Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood (2003) 1.09
Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells. J Allergy Clin Immunol (2013) 1.07
Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells. J Am Coll Cardiol (2007) 1.06
Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia (2002) 1.06
Interferon-α inhibition by intravenous immunoglobulin is independent of modulation of the plasmacytoid dendritic cell population in the circulation: comment on the article by Wiedeman et al. Arthritis Rheumatol (2014) 1.05
Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J Immunol (2010) 1.05
Is defective lymphatic drainage a trigger for lymphoid neogenesis? Trends Immunol (2006) 1.02
Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci (2007) 1.01
Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol (2010) 1.00
High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A (2005) 0.99
Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant (2008) 0.98
Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. J Thorac Cardiovasc Surg (2005) 0.98
Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J Rheumatol (2012) 0.98
Cartography of gene expression in CD8 single cells: novel CCR7- subsets suggest differentiation independent of CD45RA expression. Blood (2007) 0.98
Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol (2005) 0.98
Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant (2002) 0.97
Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer (2008) 0.97
Rapid cooling preserves the ischaemic myocardium against mitochondrial damage and left ventricular dysfunction. Cardiovasc Res (2009) 0.96
Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev (2008) 0.96
DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci U S A (2009) 0.94
Reduced immunoregulatory CD31+ T cells in the blood of atherosclerotic mice with plaque thrombosis. Arterioscler Thromb Vasc Biol (2005) 0.93
Common variable immunodeficiency: the immune system in chaos. Trends Mol Med (2005) 0.93
A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2007) 0.92
Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2003) 0.92
Transgenic mice expressing nitroreductase gene under the control of the podocin promoter: a new murine model of inductible glomerular injury. Virchows Arch (2009) 0.92
Circulating human basophils lack the features of professional antigen presenting cells. Sci Rep (2013) 0.92